Rocket Pharmaceuticals has reported a positive safety update for RP-A501 from the first 3 patients treated under a modified phase 2 protocol in Danon disease.
Rocket Pharmaceuticals has reported a positive clinical safety update from the initial 3 patients treated under a modified protocol for its
"These encouraging early safety observations from the initial three patients treated with RP-A501 reinforce our strong confidence in the program that was built on transformative results from the phase 1 trial which reflect the potential of gene therapy to address genetic cardiomyopathies," said
The 3 patients received RP-A501 at a recalibrated dose of 3.8 x 1013 GC/kg, together with a refined
"The recalibrated phase 2 dose was selected with the expectation that it will deliver potency consistent with the dose at which RP-A501 demonstrated meaningful efficacy in patients in phase 1," said
Rocket is actively engaging with FDA to align on a path to dosing additional patients and completing the pivotal phase 2 trial under the modified protocol, with a regulatory pathway update expected in the second half of 2026. The company also said it remains on track to provide a comprehensive Danon disease program update in the second half of 2026.1
RP-A501 is an
RP-A501 holds FDA regenerative medicine advanced therapy, fast track, rare pediatric disease, and orphan drug designations in the United States, along with advanced therapy medicinal product and priority medicines designations in the European Union.1
Danon disease is a rare, X-linked, multi-organ lysosomal disorder caused by mutation of the gene encoding LAMP2, a mediator of autophagy expressed primarily in heart, skeletal muscle, and brain tissue.1,2 The mutation causes accumulation of autophagosomes and glycogen, particularly in cardiac muscle, ultimately leading to heart failure and, in male patients, frequent death during adolescence or early adulthood.1,2 Cardiac transplantation is currently the only definitive treatment option, carries substantial complications, and is not considered curative, underscoring the need for disease-modifying approaches such as gene therapy in this population.1
RP-A501 is among a small number of gene therapies in clinical development for inherited cardiovascular disorders, a category that has lagged others given the complexity of expressing a functional transgene in cardiac tissue. Rocket has described RP-A501 as the first gene therapy for a cardiovascular condition to demonstrate safety and efficacy in clinical studies.1 A successful recalibrated dosing and immunomodulation strategy could inform dose-selection and safety approaches for other AAV-based cardiac gene therapies, particularly around managing complement-mediated toxicities such as TMA that have affected AAV programs in other disease areas.
